Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model.

Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model.

Ras activation has been correlated with malignant and metastatic cancer phenotypes and poor prognosis for cancer patients. In the preclinical setting, Ras activation by mutation or EGFR amplification results in increased clonogenic cell survival and decreased tumor growth delay following irradiation...

Bibliografske podrobnosti
Main Authors:	Cengel, K, Mckenna, W
Format:	Journal article
Jezik:	English
Izdano:	2005

Podobne knjige/članki

Molecular radiosensitization of pancreatic carcinoma cell lines in vivo and in vitro
od: Cengel, K, et al.
Izdano: (2004)

The influence of Ras pathway signaling on tumor radiosensitivity.
od: Kim, I, et al.
Izdano: (2004)

Modifying radiosensitivity in tumors: Targeting the Ras-PI-3 kinase pathway.
od: Muschel, R, et al.
Izdano: (2001)

The clinical implications of gemcitabine radiosensitization.
od: Doyle, T, et al.
Izdano: (2001)

Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
od: Kim, I, et al.
Izdano: (2005)

Molecular Biomarkers for Predicting Cancer Patient Radiosensitivity and Radiotoxicity in Clinical Practice
od: Angeliki Gkikoudi, et al.
Izdano: (2023-11-01)

Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1
od: Isabel Freund, et al.
Izdano: (2020-05-01)

Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
od: Brunner, T, et al.
Izdano: (2005)

Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic
od: Yuewen Zhang, et al.
Izdano: (2022-07-01)

Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.
od: Cengel, K, et al.
Izdano: (2007)

Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting
od: Katharina Hintelmann, et al.
Izdano: (2020-08-01)

Targeting active RAS with molecular glue
od: Wenjing Su, et al.
Izdano: (2024-12-01)

Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia
od: Taeko Kaburagi, et al.
Izdano: (2021-03-01)

Targeting RAF dimers in RAS mutant tumors: From biology to clinic
od: Huanhuan Yin, et al.
Izdano: (2024-05-01)

PHOTOSENSITIZERS AS RADIOSENSITIZING AGENTS IN EXPERIMENTAL AND CLINICAL NEUROONCOLOGY
od: D. A. Tzerkovsky
Izdano: (2017-09-01)

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.
od: Prevo, R, et al.
Izdano: (2008)

Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts
od: Lydia Koi, et al.
Izdano: (2023-08-01)

Assessment of clinical radiosensitivity in patients with head-neck squamous cell carcinoma from pre-treatment quantitative ultrasound radiomics
od: Laurentius Oscar Osapoetra, et al.
Izdano: (2021-03-01)

Editorial: Radiotherapy for esophageal cancer: Molecular mechanism and novel targets to improve radiosensitivity
od: Yanqing Liu, et al.
Izdano: (2023-04-01)

Targeting the organelle for radiosensitization in cancer radiotherapy
od: Xiaoyan Sun, et al.
Izdano: (2024-04-01)

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
od: Md Entaz Bahar, et al.
Izdano: (2023-12-01)

Increasing radiosensitivity by alleviating tumour hypoxia: a drug screen reveals atovaquone as a clinical candidate
od: Ashton, T, et al.
Izdano: (2016)

The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives
od: Zhang Y, et al.
Izdano: (2025-03-01)

Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
od: Radu O Minea, et al.
Izdano: (2020-01-01)

Physiological Responses of Post-Dietary Effects: Lessons from Pre-Clinical and Clinical Studies
od: Christy Yeung, et al.
Izdano: (2021-01-01)

Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects
od: Zhi‐Rui Zhou, et al.
Izdano: (2018-07-01)

Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
od: Sandra Cotino-Nájera, et al.
Izdano: (2023-11-01)

Ras inhibitors and radiation therapy.
od: Jones, H, et al.
Izdano: (2001)

Targeting Mcl-1 for Radiosensitization of Pancreatic Cancers
od: Dongping Wei, et al.
Izdano: (2015-02-01)

Lessons learned from pre-clinical testing of xenogeneic decellularized esophagi in a rabbit model
od: Edward Hannon, et al.
Izdano: (2022-10-01)

Radiation sensitization by inhibition of activated Ras.
od: Brunner, T, et al.
Izdano: (2004)

Radiosensitization: Studies and Modern Approaches to Cellular Radiosensitivity
od: Juan C. Alamilla-Presuel
Izdano: (2023-09-01)

Targeting acid ceramidase to improve the radiosensitivity of rectal cancer
od: Clifford, R, et al.
Izdano: (2020)

Imatinib radiosensitizes bladder cancer by targeting homologous recombination.
od: Qiao, B, et al.
Izdano: (2013)

Multi target analysis of HeLa cells radiosensitivity
od: Khairuddin, Ili Zawani
Izdano: (2015)

Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer
od: Rachael E. Clifford, et al.
Izdano: (2020-12-01)

Molecular inhibition of RAS signalling to target ageing and age-related health
od: Mihails Laskovs, et al.
Izdano: (2022-10-01)

Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning
od: Sarah Rouhana, et al.
Izdano: (2021-12-01)

Depletion of Signal Recognition Particle 72kDa increases radiosensitivity
od: Prevo, R, et al.
Izdano: (2017)

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
od: Al-Assar, O, et al.
Izdano: (2016)